iComChain


Book a Consultation


The Complete Peptide Policy Map 2026: Every Platform’s Rules in One Place

By /

Why this page exists

If you run a research-peptide brand, you’ve probably had this experience twice a year. An account gets disabled. You go looking for the rule you broke. And the rule isn’t where you expected it — it’s in four places that say slightly different things, or it’s a catch-all sentence that never uses the word “peptide” at all.

That’s genuinely the state of this category in 2026. Google’s healthcare policy runs to thousands of words and doesn’t name peptides once. TikTok names them explicitly, twice. Amazon’s policies sit behind a seller login. Shopify’s Acceptable Use Policy is a page of principles that hands the hard questions to its payment processors. Meanwhile the FDA has issued a run of warning letters through 2026 treating “research use only” labeling as evidence of intent rather than a defense, and the MHRA has done something structurally similar in the UK.

So the rules are real, they’re enforceable, and they’re scattered. This page is the map. For every surface your brand touches — advertising, marketplaces, storefront, payments, email, SMS, certification, and the two regulators that matter most — you get what the published policy actually says, a link to the primary source, what triggers enforcement in practice, and what a compliant setup looks like. Where a platform has no published rule naming this category, we say so plainly rather than filling the gap with a guess.

Starting from zero? Read our peptide compliance guide first, then come back here for the surface-by-surface detail.

The map at a glance

Platform Can you sell? Can you advertise? Key gate
Google Ads N/A Rarely, and never with drug-effect claims Catch-all “unapproved substances” bullets; no peptide named
Google Merchant Center & Shopping N/A Very difficult Healthcare policy plus misrepresentation; suspensions cite both
Meta N/A No, for anything reading as a drug “Unsafe substances” prohibition; written permission for pharma
TikTok No No Names “peptide hormones” and GLP-1 by category
Amazon Effectively no Only what you can list Unapproved-drug enforcement; policies are login-gated
Shopify Yes, storefront-wise N/A AUP is permissive; Shopify Payments defers to processors
Other e-commerce platforms Usually yes N/A Hosting is rarely the constraint; payments are
Payment processors This is the real gate N/A “Pseudo-pharmaceuticals” clauses; RUO reads as a red flag
Email platforms N/A Depends on provider Klaviyo prohibits pharma-adjacent businesses outright
SMS carriers N/A Practically no Carrier-level content vetting, not a published peptide rule
LegitScript N/A Unlocks some ad surfaces Treats peptides as high-risk; RUO framing counts against you
US (FDA) Depends entirely on claims N/A Intended use from your own site; RUO disclaimers rejected
UK (MHRA) High risk No Medicinal product by presentation or by function

Google Ads

Google’s Healthcare and medicines policy is the governing document, and the first thing to understand is what it does not contain. We searched the current policy and its linked non-exhaustive list of unapproved pharmaceuticals and supplements for peptide terminology — peptide, BPC-157, semaglutide, tirzepatide, ipamorelin, CJC-1295, sermorelin, melanotan, tesamorelin, growth hormone. As of August 2026, none of them appear. Operators sometimes read that absence as permission. It is not.

Enforcement runs through catch-all language instead. Under “Unapproved substances,” Google prohibits “herbal and dietary supplements with active pharmaceutical or dangerous ingredients,” products that imply they are as effective as prescription drugs or controlled substances, products marketed as safe or effective for preventing or treating a disease without government approval, products subject to government regulatory action or warnings, and products with names confusingly similar to an unapproved pharmaceutical. A research compound with a mechanism-of-action claim on the landing page satisfies more than one of those simultaneously.

What triggers enforcement, in order of frequency: landing-page copy that describes a physiological effect in humans; product names that map onto a known prescription molecule; testimonials or reviews describing personal results; dosing tables; and any before-and-after imagery. Google reviews the destination, not only the ad, so a clean ad pointing at a claim-heavy page still fails.

A compliant setup means the ad, the keyword, and the destination all read as laboratory supply rather than therapy. That means specification-led product pages, no human-subject language, no dosing guidance, and reviews moderated so that outcome anecdotes do not sit under a research compound. Note also that the July 2025 healthcare update confirms warning-before-suspension for this policy family: violations “will not lead to immediate account suspension without prior warning,” with at least seven days’ notice. Use that window.

Our detailed treatment is in the Google Ads policy for peptides and the tactical walkthrough in running research peptides on Google Ads in 2026.

Google Merchant Center and Shopping

Merchant Center applies its own Healthcare and medicines policy, which is close to the Ads version but consequential in a different way: it governs whether your products exist in Shopping and free listings at all, and suspension is account-level rather than item-level.

The policy prohibits products that make false or misleading health claims and products marketed in a way that implies they are safe or effective for preventing, curing, or treating a condition. It separately prohibits products with names that are or may be confusingly similar to anabolic steroids, weight-loss drugs, prescription drugs, or controlled substances. Prescription drugs themselves are restricted rather than prohibited, permitted in the US and Canada only for pharmacies certified by LegitScript or NABP.

The second policy that catches peptide brands is misrepresentation, and in our experience it accounts for more suspensions in this category than the healthcare policy does. Misrepresentation covers representing your products “in a way that isn’t accurate, realistic, and truthful,” enticing customers “under false or unclear pretenses,” offering products you lack the licenses to provide, and claims that entice with an improbable result. A store that sells research compounds while its blog, meta descriptions, and structured data describe human benefits is misrepresenting the offer regardless of what the product page disclaimer says.

What triggers enforcement: mismatch between feed titles and landing pages, schema markup carrying health claims Google’s crawler picks up even when the visible page is clean, About and FAQ pages written for a consumer audience, and shipping or returns copy that assumes personal use.

A compliant setup treats the whole domain as reviewable surface, not just the products in the feed. Start with Merchant Center for research peptides, then the misrepresentation fix if you are already flagged, and the health products suspension guide for account-level recovery.

Meta

Meta’s Drugs and Pharmaceuticals advertising standard states that advertisers “can’t run ads that promote the sale or use of illicit or recreational drugs, or other unsafe substances” as determined by Meta. That last clause is the operative one. Meta reserves the judgment to itself, does not publish a substance list comparable to Google’s, and does not name peptides.

Prescription drugs sit in a permission tier: qualified advertisers may promote them with Meta’s written approval, on evidence that they are appropriately licensed or otherwise established as lawful in the countries they target, with no targeting of under-18 audiences. CBD requires LegitScript certification plus written permission and is limited to the United States. There is no equivalent published pathway for research compounds, which means a peptide brand is not applying for an exception — it is trying to stay outside a prohibition whose boundary Meta defines case by case.

We should be precise about a limit in our own research: Meta’s Health and Wellness advertising standard is rendered client-side and we could not extract its text through automated retrieval as of August 2026, so we are not quoting it here. What is verifiable from the Drugs and Pharmaceuticals standard is enough to plan around.

What triggers enforcement on Meta is different from Google. Meta’s classifiers weight creative heavily — body imagery, transformation framing, syringe or vial visuals, and copy addressed to a personal outcome. It also weights the Page and its organic content, so a compliant ad running from a Page whose reels describe personal protocols is exposed. Rejections frequently escalate to ad account and Business Manager restriction rather than staying at the creative level.

A compliant setup on Meta is narrow: institutional and laboratory-audience creative, no bodies, no outcome language, an ad account cleanly separated from any consumer-facing brand assets, and organic content held to the same standard as paid. See Meta ads for peptides for the working detail, and GLP-1 advertising compliance if any part of your catalog touches that space.

TikTok

TikTok is the one major platform that names this category directly, which makes it the least ambiguous and the most closed. The TikTok Shop Prohibited Products Policy bars performance-enhancing drugs including “anabolic steroids, peptide hormones, SARMs (Selective Androgen Receptor Modulators).” It separately prohibits “medicinal supplements, including steroids, sexual enhancement or performance supplements” and products requiring a prescription.

The weight-management provisions close the remaining gap. The policy states that products and supplements claiming to aid weight management, fat reduction, or similar goals are strictly prohibited, and it restricts products referencing “GLP,” “GLP-1,” or “Glucagon-like peptide-1” except for supportive products aimed at people already using GLP-1 medication.

On the advertising side, TikTok’s Healthcare and Pharmaceuticals policy requires that all healthcare products advertised “must be in compliance with all applicable laws,” prohibits prescription medicines across listed markets, and permits supplements only where they meet local regulatory approval with 18+ targeting. The Weight Management policy prohibits exaggerated weight-loss or muscle-gain claims and age-gates any such claim.

What triggers enforcement: essentially any listing or ad in the category, since the category itself is named. Enforcement here is not claim-dependent in the way Google’s is. Sellers also get caught by creator content, since TikTok attributes affiliate and branded content back to the shop.

A compliant setup on TikTok, for a research-peptide brand, is not selling or advertising the compounds there. The realistic use of TikTok is brand and education content that never lists, prices, or links a prohibited product, with commerce living on your own domain. Anything else is a matter of time. If organic discovery matters to you, put the effort into peptide SEO instead, where the surface is yours.

Amazon

Amazon requires an honest caveat. Its two governing documents — the Drugs and drug paraphernalia restricted-products policy and the dietary supplements policy — are served from Seller Central behind an authenticated session, and as of August 2026 we could not retrieve their text through public fetch. We are not going to quote a policy we could not read. What follows is what is verifiable and what we observe in practice.

What is verifiable is the framework. Amazon operates a Restricted Products program that prohibits unapproved drugs, and it enforces at the ASIN and account level with the phrase sellers report seeing in notices: the product “has been identified as an unapproved drug product.” Amazon separately requires dietary supplements to meet documentation standards including GMP evidence and testing records. Neither framework contains a category that a research compound fits. A peptide is not a dietary supplement under US law in any settled sense, and if it is presented as having an effect on the body it falls toward the unapproved-drug side.

What triggers enforcement: automated listing scans against ingredient and molecule dictionaries, competitor reports, and the compliance document request that follows. Once Amazon asks for supplement compliance documents for a product that is not a supplement, there is no answer that resolves it. Enforcement typically escalates from listing removal to a restricted-products policy violation on the account health dashboard, and repeat violations put selling privileges at risk.

A compliant setup on Amazon means a bright line: sell laboratory consumables, glassware, or genuinely non-drug ancillary products there if you want the channel, and keep research compounds entirely off the marketplace. Do not attempt to list under a supplement category with an RUO disclaimer, which is the single most common way brands convert a listing problem into an account problem. Our research peptide compliance checklist covers the channel-separation decisions this implies.

Shopify

Shopify is more permissive than most operators expect, and the reason is architectural. The Shopify Acceptable Use Policy is a short document of principles rather than an enumerated prohibited-goods list. Its core rule is that you can’t use Shopify to do anything that is illegal where you do business. It restricts content facilitating intentional self-harm, and it notes that Protected Health Information subject to HIPAA is not supported on the platform. It does not name pharmaceuticals, supplements, research chemicals, or peptides.

The constraint sits one layer down. The Shopify Payments Terms of Service states that the categories considered Prohibited or Restricted Businesses “are provided by each Payment Processor in your Designated Country.” In the United States that means Stripe’s list governs, and Stripe prohibits “pseudo-pharmaceuticals or nutraceuticals that are not safe or make harmful claims.” So Shopify will host you; Shopify Payments frequently will not keep you.

What triggers enforcement: almost always a payments review rather than a hosting review. The pattern is a risk team looking at the storefront, reading claim language or dosing content, and closing the payments account — after which the store is technically live but cannot take money. Chargeback ratios and sudden volume spikes accelerate the review.

A compliant setup separates the two problems. Treat Shopify as your storefront and solve payments independently with a processor that has underwritten your category knowingly, rather than relying on the default integration and hoping the review never comes. Keep the storefront’s claim surface clean regardless, because the storefront is the evidence the payments reviewer reads. Our comparison of storefront options is in choosing an e-commerce platform for peptides.

Other e-commerce platforms

Beyond Shopify, the platform question splits into three groups, and the split matters more than any individual vendor’s terms.

Self-hosted software — WooCommerce on your own WordPress install, or a comparable open-source stack — has no acceptable use policy governing your products at all, because nobody is hosting your commerce logic. Your constraints become your web host, your CDN, and your payment processor. This is why a meaningful share of established research-peptide operations run self-hosted: it removes one entire category of platform risk.

Hosted SaaS platforms other than Shopify — BigCommerce, Wix, Squarespace, and similar — publish acceptable use terms that are broadly similar in shape to Shopify’s, with the same structural feature: the storefront terms are general, and the binding constraint arrives through the integrated payments provider. We would rather state that structural point than quote specific clauses. As of August 2026 we could not verify, from primary policy text, a published rule at any of these vendors naming research peptides or research chemicals as a prohibited category.

Third-party marketplaces — Walmart Marketplace, eBay, Etsy — publish prohibited-products policies covering drugs, drug paraphernalia, and dietary supplements, and behave like Amazon in practice. They are curated inventories with their own compliance teams and no category that fits a research compound.

What triggers enforcement across all three: for self-hosted, host abuse complaints and processor review; for SaaS, processor review; for marketplaces, catalog scanning.

A compliant setup means deciding early whether you are optimizing for convenience or for durability. Convenience is a hosted platform with bundled payments, which works until a risk team reads your site. Durability is a storefront you control plus a processor that underwrote you with full knowledge of the category. Most brands that survive several years end up at the second.

Payment processors

Payments are where this category actually lives or dies, and it is the surface where the published rules are clearest.

Stripe’s Prohibited and Restricted Businesses list prohibits “pseudo-pharmaceuticals or nutraceuticals that are not safe or make harmful claims,” and places online pharmacies, card-not-present prescription-only products and pharmaceuticals, telemedicine, and prescription delivery in a restricted tier requiring additional diligence. Most mainstream processors carry an equivalent clause.

More important is how the risk industry has been told to read RUO framing. LegitScript’s Understanding Peptides: A Q&A Guide for Payment Processors and Online Platforms instructs reviewers that merchants “offering research chemicals that prominently state that their products are not intended for human consumption are, perhaps counterintuitively, more likely to be engaged in unapproved peptides sales.” Its companion analysis puts it more bluntly: such language “is often a red flag rather than a legal protection.” The guide lists the specific signals underwriters are told to look for — no verification that the buyer is a professional researcher, catalogs dominated by known problematic compounds such as Melanotan II, BPC-157, CJC-1295 and ipamorelin, and clinical branding that mimics a legitimate laboratory.

Sit with that inversion, because it is the most misunderstood fact in this business. The disclaimer that protects you in one framing raises your risk score in another. It does not follow that you should remove it — the FDA position below makes clear you need genuine RUO substance — but it does follow that the disclaimer is not doing the work founders think it is doing.

What triggers enforcement: underwriting review at onboarding, periodic re-review, volume spikes, chargeback ratios above card-network thresholds, and acquirer-level portfolio decisions that terminate accounts with no merchant-specific cause.

A compliant setup means full disclosure at underwriting, a processor that has priced the category deliberately, redundancy so that one termination is not an extinction event, and buyer-verification practices that make your RUO framing substantive. Detail in payment processors for peptide brands.

Email platforms

Email is where founders are most often blindsided, because the platform that hosts your highest-value owned channel may prohibit your business outright in a document nobody reads at signup.

Klaviyo’s Acceptable Use Policy, last updated 9 April 2026, is the clearest example. It prohibits businesses dealing in “prescription medications, pharmaceutical products or services, medical therapies, telehealth, and other related technologies, products, or services.” Separately it prohibits soliciting, storing, processing, sending, or transmitting medical records, health information, or Protected Health Information as defined under HIPAA. And it reserves the right “to evaluate and restrict any use cases related to illegal or controlled substances.” For SMS specifically it bans content involving prescription medication that cannot legally be sold over the counter.

Read those three provisions together. The first can catch a peptide brand on the “related products or services” tail. The second catches you the moment you collect a health-related survey response, a condition field, or a quiz answer, which several peptide brands do as a segmentation tactic. The health-data clause is often the one that actually gets enforced, because it is objective and detectable.

What triggers enforcement: signup review, spam-complaint thresholds, deliverability escalations that put a reviewer in front of your account, and custom-property audits that surface health fields.

A compliant setup means picking a provider whose terms you have read against your actual business, never collecting health information into the marketing stack, keeping campaign content in the same laboratory-supply register as your site, and maintaining an export of your list plus a warm secondary sending domain so that a termination is an inconvenience rather than a rebuild. We compare the market in which email platforms will ban a peptide brand.

SMS carriers

SMS is governed differently from every other surface on this map, and understanding the difference explains why campaigns get blocked with no policy citation.

The published industry document is CTIA’s Messaging Principles and Best Practices. Its content section directs message senders to prevent content that is “unlawful, harmful, abusive, malicious, misleading, harassing, excessively violent, obscene/illicit, or defamatory,” and content that deceives or intends to deceive. As of August 2026 we could not find a published CTIA rule naming peptides, research chemicals, or supplements as a category. The document is general.

The real gatekeeping happens below the published layer. US carriers vet 10DLC campaigns through registration, and the aggregators that broker that registration apply their own content rules — commonly summarized as SHAFT, covering sex, hate, alcohol, firearms, and tobacco, extended in practice to controlled substances and pharmaceuticals. These rules are enforced through campaign rejection and message filtering rather than through a policy page you can cite or appeal against. Your registration is simply denied, or your throughput quietly collapses.

What triggers enforcement: campaign registration review of your sample messages and website; keyword filtering on molecule names in message bodies; and complaint rates, which carriers treat as decisive.

A compliant setup means keeping molecule names, dosing language, and health outcomes out of message bodies entirely, using SMS for transactional and logistics messaging rather than product marketing, registering your campaign with sample copy that reflects what you will actually send, and maintaining consent records that survive an audit. Many peptide brands conclude that SMS is not worth the operational overhead, and that is a defensible call — the same effort applied to email and organic search returns more.

LegitScript

LegitScript is not a platform. It is the certification body several platforms delegate to, which makes its posture on peptides more consequential than its formal authority suggests.

Its certification programs cover healthcare, addiction treatment, and CBD, with the healthcare certification enabling advertising on Google, Microsoft, Meta, LinkedIn, and TikTok. Google’s Merchant Center healthcare policy names LegitScript certification as the route for prescription-drug pharmacies in the US and Canada, and Meta names it for CBD.

The critical point for this audience is that LegitScript has published dedicated guidance treating peptides as an emerging high-risk category. Its analysis states that unapproved peptide sales “can expose businesses to regulatory enforcement, card network fines, and reputational harm,” flags rising concern about unauthorized versions of high-profile GLP-1 peptides such as semaglutide and tirzepatide, and notes that merchants selling these compounds often “mirror the aesthetics of professional laboratories” while operating outside the law. Its work on peptides in dietary supplements observes that the FDA has not approved many peptides for human use and has flagged safety concerns about specific compounds.

As of August 2026 we could not find a published LegitScript certification pathway for research-use-only peptide sellers. There is no product that fits. The healthcare certification is built for licensed pharmacies, telehealth providers, and manufacturers.

What this means practically: certification is not a door you can walk through to unlock Google and Meta for research compounds. It is a door for a different business model. Some peptide operators eventually restructure into a licensed pharmacy or telehealth entity precisely because it is the only structure that certification recognizes — a genuine strategic option, and a completely different company. We work through that decision in LegitScript certification for peptides.

United States (FDA)

The FDA position is the most settled thing on this map, and 2026 has made it unmistakable through enforcement rather than new rulemaking.

The legal test is intended use. A product is a drug if it is intended to affect the structure or function of the body or to treat a condition, and intent is established from the totality of evidence — chiefly your own marketing. Warning letters issued through 2026 apply this consistently. In a June 2026 letter the agency wrote that “despite statements on your product labeling marketing your products for ‘RESEARCH USE ONLY’ and ‘not for human consumption,’ evidence obtained from your product labeling, including your website establishes that your products are intended to be drugs for human use.” A March 2026 letter reaches the same conclusion in the same words, citing site copy about appetite and blood sugar. Both cite sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act — unapproved new drugs introduced into interstate commerce.

The FDA’s June 2026 statement on unapproved GLP-1 drugs makes the pattern explicit, warning about companies selling unapproved drugs “falsely labeled ‘for research purposes’ or ‘not for human consumption'” that are in fact sold to consumers with dosing instructions.

So the disclaimer is not the control. The claims are. What triggers enforcement: therapeutic or physiological claims anywhere on your property, dosing instructions, consumer-facing testimonials, reconstitution guides written for people, and sales channels that make no attempt to verify a research buyer.

A compliant setup means your entire published surface supports the RUO characterization — specification-led pages, no human-use guidance, no outcome testimonials, meaningful buyer qualification, and certificates of analysis presented as laboratory documentation rather than quality reassurance for a consumer. See peptide product page copy and COAs and third-party testing.

United Kingdom (MHRA)

The UK reaches a similar destination by a different legal route, and the route is arguably stricter.

Under the Human Medicines Regulations 2012, a product is a medicinal product if it satisfies either of two limbs. By presentation: any substance “presented as having properties for treating or preventing disease in human beings.” By function: any substance which may be used in or administered to human beings “with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action.” The MHRA sets this out in Guidance Note 8, A guide to what is a medicinal product.

The function limb is the one that matters. A compound can be caught by what it does, independent of any claim you make, which means a disclaimer cannot save a product that has a pharmacological action. Guidance Note 8 also confirms that “information on the internet about a product and its uses is not excluded from the definition of ‘advertisement’,” and that linked sites and customer testimonials are treated as evidence when the MHRA determines status.

The MHRA has been visibly active. Its June 2026 warning on promoting weight-management medicines restates that medicines must hold a licence before being marketed and that prescription-only medicines cannot be advertised to the public — including through category references such as “oral GLP-1s” or waiting lists. Separate enforcement actions have involved arrests and seizures around illegal weight-loss medicine supply.

What triggers enforcement: UK-targeted marketing, GBP pricing, UK fulfilment, and any claim reachable from a UK IP address. A compliant setup for a US-based seller usually means genuinely excluding the UK — geo-restricted checkout and shipping, not just a footer notice. Detail in MHRA notices for UK research-peptide sellers.

Where you actually stand

Read the map end to end and a shape emerges that is more coherent than any single policy page suggests.

First, almost no platform bans peptides by name. TikTok does. Nobody else in the top tier does. What everyone has instead is a catch-all — Google’s “active pharmaceutical or dangerous ingredients,” Meta’s “other unsafe substances,” Stripe’s “pseudo-pharmaceuticals,” the MHRA’s function limb. This means your enforcement risk is not determined by your molecule. It is determined by how your product is presented. Two brands selling identical compounds can have completely different outcomes, and routinely do.

Second, the disclaimer does opposite work in different rooms. To the FDA and the MHRA, an RUO statement is necessary but nowhere near sufficient; they will read past it to your claims. To a payments underwriter following LegitScript’s guidance, a prominent “not for human consumption” notice is an affirmative risk signal. The resolution is not to remove the disclaimer. It is to make the disclaimer true across every surface, so that it describes your business rather than decorating it.

Third, the surfaces are not independent. Google reviews your landing page. A payments underwriter reads your storefront. The MHRA counts linked sites and testimonials as advertising. The FDA quotes your website back at you in a warning letter. There is one evidence base — your published claim surface — and every gatekeeper reads it. Cleaning up ad copy while leaving a claim-heavy blog live solves nothing.

So a compliant peptide operation in 2026 looks like this. A storefront you control, on infrastructure that does not hold your commerce hostage. A payment processor that underwrote you knowingly, plus a backup. Product pages that are specification documents: purity, molecular weight, storage, CoA, no human-use guidance, no dosing, no testimonials describing personal results. No health data collected anywhere in the marketing stack. Email on a provider whose terms you have actually read, with an exportable list. SMS limited to transactional messaging, or skipped. No presence on TikTok Shop or Amazon for the compounds themselves. Geographic exclusion of the UK unless you have taken specific advice. And paid media treated as a bonus rather than a foundation, with organic search and owned audience carrying the load — because search is the one channel where nobody can switch you off overnight.

That is a narrower business than most founders want. It is also the version that is still trading in three years. This article is general information about published platform and regulatory policy, not legal advice; take advice from a qualified attorney on your specific products and claims.

Frequently Asked Questions

Does Google explicitly ban peptides?

No, and it never has to. As of August 2026, neither the Google Ads Healthcare and medicines policy nor the linked list of unapproved pharmaceuticals and supplements names peptides or any specific peptide compound. Enforcement runs through catch-all provisions instead: supplements with active pharmaceutical ingredients, products implying prescription-drug equivalence, and products marketed as effective for treating a condition without approval. In practice, your claims determine your outcome, not your molecule. It also means an approval today isn’t durable protection, because those catch-alls can be applied to the same product at any later review.

Will a “research use only” disclaimer protect my account?

By itself, no, and on payments it can actively hurt. FDA warning letters in 2026 state directly that despite RUO and “not for human consumption” labeling, website evidence established that products were intended as drugs for human use. LegitScript’s guidance tells payment processors that prominent “not for human consumption” language makes a merchant, perhaps counterintuitively, more likely to be selling unapproved peptides. So the disclaimer only functions when the rest of your operation supports it: laboratory-audience copy, no dosing guidance, no personal-outcome testimonials, and real buyer qualification.

Can I sell peptides on Amazon or TikTok Shop?

On TikTok Shop, no. Its Prohibited Products Policy names peptide hormones and SARMs directly, and separately prohibits weight-management products and most GLP-1 references. Amazon is effectively closed too, though its policies sit behind a seller login and we could not retrieve their text publicly. There is no Amazon category a research compound fits. It isn’t a dietary supplement, and anything presented as affecting the body falls toward unapproved drug. Sellers who attempt a supplement listing with an RUO disclaimer typically escalate a listing removal into an account-level violation.

What is the single most common reason peptide brands get suspended?

Inconsistency across surfaces. The product page is carefully written, and then the blog, the FAQ, the reviews, the schema markup or the founder’s social account describes human benefits. Google’s Merchant Center misrepresentation policy, the FDA’s intended-use analysis and the MHRA’s treatment of linked sites and testimonials all evaluate your whole published presence, not the one page you cleaned. That’s the gap. Brands that survive audit their entire domain, archived posts and structured data included, rather than only the pages they expect a reviewer to open.

Is Shopify safe for a peptide brand?

The platform and the payments are two different questions. Shopify’s Acceptable Use Policy is unusually permissive: it prohibits illegal activity and self-harm content, notes it does not support HIPAA-covered health information, and doesn’t enumerate pharmaceuticals or supplements. The risk arrives through Shopify Payments, whose terms delegate prohibited-business definitions to the underlying processor. In the US that means Stripe’s list, which prohibits pseudo-pharmaceuticals and nutraceuticals making harmful claims. So Shopify will usually host you while the bundled payments account may be closed after review. Solve payments separately rather than relying on the default.

Does LegitScript certification unlock Google and Meta for peptides?

Not for research-use-only sellers. LegitScript’s healthcare certification is built for licensed pharmacies, telehealth providers and pharmaceutical manufacturers, and Google and Meta reference it for those business models plus CBD. As of August 2026 we could not find a published certification pathway covering research peptides. LegitScript has instead published guidance treating peptides as a high-risk category for platforms and payment processors. Certification becomes relevant only if you restructure into a licensed entity, and that is a genuinely different company rather than a compliance upgrade.

Can I email or text my customers about peptides?

Email depends entirely on your provider. Klaviyo’s Acceptable Use Policy, updated 9 April 2026, prohibits businesses dealing in prescription medications, pharmaceutical products or services, medical therapies and telehealth, and separately prohibits storing or transmitting health information. Other providers draw the line differently, so read the terms against your actual business before you build a list there. SMS is harder. Carriers and aggregators vet campaign content without a published peptide rule, and product marketing with molecule names is routinely filtered. Keep SMS transactional.

Do I need to worry about the UK if I only ship to the US?

You are clear only if you are genuinely not selling into the UK. The MHRA’s function limb can classify a compound as a medicinal product based on what it does, independent of your claims, and its guidance treats website information, linked sites and testimonials as advertising. If your site accepts UK orders, prices in GBP, or ships there, you’re exposed regardless of where you’re incorporated. Real exclusion means geo-restricted checkout and shipping rules, not a footer disclaimer. And it should be tested rather than assumed.

Working with a partner who knows this terrain

The map above is the terrain, not the route. Where a brand actually ends up depends on its catalog, its markets, its processor relationships, and how much of its claim surface has accumulated over the years without review. If you would rather not work through thirteen policy regimes alone, we do this full time as a peptide marketing agency built specifically for regulated e-commerce, from Merchant Center recovery through payments architecture and organic growth. Book a free 15-minute consultation and we will tell you honestly where you stand and what we would fix first.

Sources

Every policy and regulatory claim in this article is drawn from the primary documents below, checked on 15 August 2026. Platform policies change without notice; verify against the current version before acting.

Related guides and services

Scroll to Top